| Literature DB >> 33083517 |
Fisayo A Olotu1, Kehinde F Omolabi1, Mahmoud E S Soliman1.
Abstract
The systematic entry of SARS-CoV-2 iene">nto host cells, as mediated by itsEntities:
Keywords: Allosteric targeting; High-affinity binding; Receptor binding domain; SARS-CoV-2; Spike protein; Virtual high-throughput screening
Year: 2020 PMID: 33083517 PMCID: PMC7561517 DOI: 10.1016/j.imu.2020.100451
Source DB: PubMed Journal: Inform Med Unlocked ISSN: 2352-9148
Fig. 1Structural architecture of SARS-CoV-2 S-protein and target human ACE2 (protease domain). A. Structural topology of the SARS-CoV-2 S-protein showing its different components. NTD, N-terminal domain; RBD, receptor binding domain; SD1, subdomain 1, SD2, subdomain 2; S1/S2, furin cleavage site 1; UH, upstream helix; L, linker region; S2’, furin cleavage site 2; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connector domain; HR2, heptad repeat 2; TM, transmembrane region, CT, cytoplasmic tail. B. 3D structure of the prefusion (S1/S2) S-protein and the interacting (protease) domain of the host hACE2 (grey).
Fig. 2Structural depiction of the modeling approach employed herein for obtaining the prefusion S-protein-hACE2 complex. A. 3D structure of the prefusion SARS-CoV-2 S-protein as retrieved from PDB (ID 6VSB)B. Retrieved 3D structure of the truncated S-protein RBD and hACE2 (PDB ID 6M0J) C. Modelled complex of prefusion SARS-CoV-2 S-protein and hACE2 as obtained via structural superposition of A and B, followed by removal of the truncated domain.
Identification and cross validation of potential allosteric sites on SARS-CoV-2 prefusion S-protein using multiple predictive algorithms.
| Predicted sites | Binding site prediction and cross-validation | Corresponding S-protein domain | |||
|---|---|---|---|---|---|
| SiteMap | Fpocket | DS 2016 Client | Prankweb | ||
| Site 1 | 65, 66, 95–115, 121–136, 202, 201, 203, 204, 205, 206, 211, 221, 222, 223 | 101, 103, 104, 108, 109, 142, 143, 144, 145, 146, 147, 178 | 92,93, 94, 95,96, 97, 98, 99, 101, 102, 103, 104, 105, 106, 117–129, 170–175, 189–194, 203–207, 223, 224, 225 | 99, 101, 102, 104, 119, 120, 121, 126, 172, 173, 175, 177, 190, 192, 203, 205 | NTD |
| Site 2 | 731-737, 791–806, 815,819, 823–828, 833–840, 951, 954, 959, 962-968 | 705-713, 720, 789, 792, 793, 794, 807, 832, 833, 834, 835, 836, 837, 840, 848, 852–863, 904, 908–910, 947-960 | 726, 727, 822–837, 845–854, 856–861, 944-963 | 828, 833, 837, 854, 856, 858, 859, 860, 956, 959, 960, 963 | FP, HR1, CD |
| Site 3 | 18, 19, 20, 21, 22, 23, 53–61, 288–293, 585–593, 623-635 | 13, 28, 47, 50, 51, 53, 54, 57, 317, 318, 372 | 37, 38, 39, 40, 41, 42, 51, 52,53, 54, 55, 195-204 | 50, 51, 52, 273, 274, 291, 292, 298, 301, 302, 304, 315, 317, 631, 632 | NTD, RBD, SD1 |
| Site 4 | 363, 364, 365, 366, 367, 368, 369, 370, 382, 383, 385, 423–434, 512, 513, 514, 515 | 355, 380, 396, 398, 412, 423, 425, 426, 429, 430, 431, 432, 433, 464, 512, 513, 514, 515, 516, 518 | 326, 327, 328, 329, 330, 331, 357, 358, 359, 360, 361, 362, 363, 380–396, 428, 429, 430, 431, 432, 513–526, 541–548, 559-580 | 355-360, 396, 398, 425, 426, 429, 430, 431, 433, 464, 466, 514, 515, 516 | RBD, SD1 |
| Site 5 | 596-603, 660–674, 697–702, 710,711, 712, 713, 714, 715, 716, 717, 718, 719, 775-781 | 769, 774, 797, 798, 800, 882, 883, 895, 896, 897, 898, 899, 902, 916, 920, 923 | 719-734, 769–785, 833, 860–875, 1069 | 729, 730, 731, 774, 775, 778, 782, 830, 863, 865, 867, 870, 1056, 1058, 1059 | SD1, CR, HR1 |
| Site 6 | 1068, 1069, 1077, 1078, 1079, 1080, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1105, 1106, 1107 | 1010, 1012, 1015, 1019, 1108, 1119, 1208, 1210, 1211, 1212, 1214, 1215, 1218 | 909. 910, 911, 1089, 1090, 1091, 1092, 1093, 1094, 1104, 1105, 1106, 1107, 1108, 1109, 1207-1216 | 1081, 1083, 1084, 1088, 1115, 1116, 1117, 1122, 1123, 1136, 1137, 1138, 1201 | SD2, βH, TM, CH |
NTD, N-terminal domain; FP, fusion peptide; HR1, heptad repeat 1; CD, connector domain; RBD, receptor binding domain; SD2, subdomain 2; SD1, subdomain 1; CH, central helix; βH – β hairpin; TM, transmembrane region.
Fig. 3Predicted allosteric sites and their locations on SARS-CoV-2 S-protein. A. 3D structure of the SARS-CoV-2 prefusion S-protein showing surface representation of the predicted Sites 1 and 2. B. Closer look at the predicted Site 1, constituent residues and starting orientation of ZINC3939013. C. Inset showing the predicted Site 2, constituent residues and binding orientation of ZINC27990463.
Characterization of the predicted allosteric sites on SARS-CoV-2 prefusion S-protein based on site attributes.
| Predicted sites | Druggability score (Dscore) | SiteScore | Surface-exposure | Pocket Size | Pocket Volume (A [ | Hydrophobicity | Hydrophilicity | Hydrogen donor/acceptor |
|---|---|---|---|---|---|---|---|---|
| 0.893 | 0.935 | 0.933 | 482 | 245.82 | 0.168 | 0.336 | 0.875 | |
| 1.046 | 0.899 | 0.794 | 503 | 294.31 | 0.243 | 0.203 | 1.922 | |
| 0.842 | 0.823 | 0.862 | 319 | 208.6 | 0.142 | 0.822 | 1.886 | |
| 0.803 | 0.817 | 0.852 | 263 | 214.30 | 0.111 | 0.613 | 2.539 | |
| 0.738 | 0.801 | 0.800 | 218 | 148.8 | 0.353 | 0.705 | 1.294 | |
| 0.711 | 0.786 | 0.696 | 267 | 237.64 | 0.392 | 0.884 | 0.634 |
Fig. 4Allosteric disruption of S-protein hACE2 binding at the RBD. Inset A-D shows the trajectorial motions of the RBD (red) and its associated hACE2 (grey) along the simulation period from the starting to the ultimate structure at 300ns. Inset A’-D’ shows systematic perturbations of the RBD and time-based displacement of the hACE2 as induced by the binding of ZINC3939013 (yellow surface) at the predicted Site 1.
Fig. 5Systematic perturbations of the S-protein RBD. Inset A’-D’ shows time-based alterations of the RBD and displacement of the hACE2 as induced by the allosteric binding of ZINC27990463 (green surface) at the predicted Site 2.
Fig. 6Relative structural stabilities of the S-protein and corresponding hACE2 among the unbound and bound (red and green) systems. A and A’ shows the overall RMSD and FE-RMSD for unbound (black), ZINC3939013-bound (red), and ZINC27990463-bound (green) S-protein. B and B’ shows overall RMSD and FE-RMSD for hACE2s associated to unbound (black), ZINC3939013-bound (red), and ZINC27990463-bound (green) S-proteins.
Estimations of relative conformational variations across the studied systems.
| Structural analysis (Å) | Unbound Spike (hACE2) | ZINC393013Spike (hACE2) | ZINC27990463Spike (hACE2) |
|---|---|---|---|
| Whole RMSD | 17.09 ± 1.1 (1.77 ± 0.23) | 13.31 ± 0.9 (1.93 ± 0.32) | 11.00 ± 2.0 (2.2 ± 0.4) |
| FE-RMSD | 11.05 ± 0.3 (1.66 ± 0.26) | 9.57 ± 0.4 (1.87 ± 0.31) | 7.61 ± 1.4 (2.6 ± 0.1) |
| FE-RMSF | 5.40 ± 1.9 (0.73 ± 0.32) | 4.87 ± 1.7 (1.39 ± 0.45) | 3.79 ± 1.2 (3.0 ± 0.82) |
| FE-RoG | 41.08 ± 0.41 (24.49 ± 0.1) | 38.4 ± 0.36 (25.01 ± 0.16) | 36.9 ± 0.61 (26.0 ± 0.22) |
| Receptor binding domain (RBD) | |||
| FE-RMSD | 4.1 ± 0.1 | 5.6 ± 0.3 | 6.1 ± 0.2 |
| FE-RoG | 15.3 ± 0.2 | 16.1 ± 0.3 | 16.2 ± 0.2 |
Fig. 7Estimations of Cα motions at the RBD domain of unbound and allosterically-bound S-proteins relative to hACE2 interactions. A. Comparative Cα RMSD plot of unbound (black), ZINC3939013-bound (red), and ZINC27990463-bound (green) S-protein RBD. B. Comparative Cα RoG plot of unbound (black), ZINC3939013-bound (red), and ZINC27990463-bound (green) S-protein RBD. C. Visual analyses of structural alterations that occurred differentially at the RBDs of unbound (black), ZINC3939013-bound (red), and ZINC27990463-bound (green) S-protein. These depictions were obtained via structural superposition of their resulting average structures.
Fig. 8Cα FE-RMSF plots showing disparate per-residue motions and conformational flexibility among unbound and ligand-bound S-proteins together with their corresponding hACE2s A. Comparative per-residue fluctuations in S-proteins of unbound (black), ZINC3939013-bound (red), and ZINC27990463-bound (green) S-protein B. Comparative per-residue fluctuations in their corresponding hACE2s.
FE-RMSF calculations of the structural components of SARS-CoV-2 S-protein in their unbound and allosterically-bound forms.
| Residual fluctuation (Å) | |||
|---|---|---|---|
| NTD | 1.35 ± 1.25 | 1.64 ± 0.52 | 1.26 ± 0.6 |
| RBD | 1.75 ± 0.7 | 1.9 ± 1.24 | 2.14 ± 0.44 |
| SD1 | 1.67 ± 0.39 | 1.53 ± 0.44 | 1.35 ± 0.3 |
| SD2 | 1.85 ± 0.49 | 1.72 ± 0.67 | 1.19 ± 0.31 |
| S2 | 1.39 ± 0.89 | 1.30 ± 0.66 | 1.15 ± 0.43 |
Fig. 9Binding orientations of the allosteric binders at the predicted S-protein sites over the terminal post-equilibrated time-frames. A-C. show ZINC3939013 orientations at Site 1 along time-frames 270-300ns A’-C’. shows the trans-domain orientations of Site 2-bound ZINC27990463 from 270-300ns of the simulated trajectory.
Binding free energy profiles of the ligand-protein complexes.
| Energy Components (kcal mol−1) | ZINC3939013-Site 1 | ZINC27990463-Site 2 |
|---|---|---|
| −49.93 ± 0.21 | −43.19 ± 0.15 | |
| −213.0 ± 1.54 | 34.68 ± 0.54 | |
| −262.9 ± 1.49 | −8.51 ± 0.56 | |
| 214.2 ± 1.38 | −21.65 ± 0.51 | |
| −7.5 ± 0.01 | −6.4 ± 0.02 | |
| 206.7 ± 1.38 | −28.05 ± 0.51 | |
| Δ | −56.2 ± 0.19 | −36.56 ± 0.26 |
| −3.5 ± 0.02 | 3.99 ± 0.1 | |
| −52.7 ± 0.26 | −32.57 ± 0.17 |
Fig. 10Ligand-residue interactions and energy contributions at the predicted allosteric sites of SARS-CoV-2 S-protein. A. Per-residue energy decomposition plot for ZINC3939013 at S-protein Site 1 A’. Complementary interaction pattern mediated by ZINC3939013 at S-protein Site 1 with constituent residues. Bond distances are also shown for crucial residues indicative of their strength B. Energy plot showing contributions of individual residues of the predicted Site 2 towards the stability of ZINC27990463. Corresponding interactions are showed in B’.